Table 1.
Characteristics of patients with hepatocellular carcinoma
| All stages (N = 8999) | Early stages (N = 6594) | Advanced stages (N = 2405) | P | |
|---|---|---|---|---|
| Age at HCC diagnosis (y) | 71.1 ± 9.5 | 71.2 ± 9.4 | 71.0 ± 9.5 | 0.492 |
| Observation period (months) | 26.2 ± 16.5 | 27.4 ± 16.8 | 22.9 ± 15.2 | <0.001 |
| Male sex (%) | 69.2% | 66.1% | 77.9% | <0.001 |
| BMI | 23.8 ± 6.3 | 23.8 ± 6.9 | 23.8 ± 3.8 | 0.962 |
| Hepatitis | ||||
| HCV | 52.0% | 55.2% | 43.0% | <0.001 |
| HBV | 19.4% | 18.9% | 20.8% | 0.050 |
| Nonviral | 16.0% | 16.2% | 15.6% | 0.455 |
| Hypertension | 53.4% | 54.1% | 51.5% | 0.029 |
| Type 2 DM | 45.8% | 45.9% | 45.7% | 0.867 |
| Cirrhosis | 39.3% | 39.3% | 39.5% | 0.883 |
| Hyperlipidemia | 15.5% | 16.0% | 14.0% | 0.022 |
| CCI | 4.9 ± 2.9 | 4.9 ± 2.9 | 4.9 ± 2.7 | 0.519 |
Means ± standard deviations are shown for continuous variables. The differences in mean values between early and advanced stages were assessed, and P‐values were calculated using the t test, Wilcoxon rank‐sum test, or Fisher's exact test. Because of the missing BMI values, 8746 patients in all stages, 6423 patients in early stages, and 2323 patients in advanced stages were analyzed. HCC, hepatocellular carcinoma; BMI, body mass index; DM, diabetes mellitus; CCI, Charlson comorbidity index.